ArticleGenes & development2021
mTOR inhibition acts as an unexpected checkpoint in p53-mediated tumor suppression.
Erratum issuedOpen access · diamondAbstract read
In one paragraph
Article in Genes & development, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Targeting p53 pathways: mechanisms, structures, and advances in therapy.Signal transduction and targeted therapy · 2023Pooled it
- Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.Frontiers in immunology · 2022Pooled it
- Genetic mutations governing ferroptosis sensitivity and resistance: a precision approach to cancer therapy.Cell death & disease · 2026Review
- A GPX1-OSBPL8 axis mediates noncanonical in vivo ferroptosis and cancer growth suppression.Cell · 2026Article
- Hepatocellular carcinoma's inflammatory secret: ferroptosis as the key.Translational cancer research · 2026Article
- p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program.Cancer discovery · 2026Article
- Distinct signaling mechanisms and proteome phenotypes are elicited by compartment-specific genetic defects of copper homeostasis.bioRxiv : the preprint server for biology · 2026Article
- Androgen receptor contributes to radioresistance through DNA repair and autophagy in AR-positive prostate cancer cells.bioRxiv : the preprint server for biology · 2025Article
- Integrative multiomic approaches reveal ZMAT3 and p21 as conserved hubs in the p53 tumor suppression network.Cell death and differentiation · 2025Article
- p53-regulated non-apoptotic cell death pathways and their relevance in cancer and other diseases.Nature reviews. Molecular cell biology · 2025Review
- Genetic profile of ferroptosis in non-small cell lung carcinoma and pharmaceutical options for ferroptosis induction.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope.Molecular cancer · 2024Review
- Ferroptosis and its Potential Determinant Role in Myocardial Susceptibility to Ischemia/Reperfusion Injury in Diabetes.Reviews in cardiovascular medicine · 2024Review
- HADHA promotes esophageal cancer progression by activating mTOR signaling and the SP1/MDM2 axis.Acta biochimica et biophysica Sinica · 2024Article
- Understanding the complexity of p53 in a new era of tumor suppression.Cancer cell · 2024Review
- p53 Acetylation Exerts Critical Roles in Pressure Overload-Induced Coronary Microvascular Dysfunction and Heart Failure in Mice.Arteriosclerosis, thrombosis, and vascular biology · 2024Article
- Current Progress of Ferroptosis Study in Hepatocellular Carcinoma.International journal of biological sciences · 2024Review
- Review
- Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases.Signal transduction and targeted therapy · 2023Review
- Sakuranin represses the malignant biological behaviors of human bladder cancer cells by triggering autophagy via activating the p53/mTOR pathway.BMC urology · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 1 institution in 1 country.
Ning KonInstitute for Cancer Genetics, Department of Pathology and Cell Biology, Columbia University, New York, New York 10032, USA.
Yang OuInstitute for Cancer Genetics, Department of Pathology and Cell Biology, Columbia University, New York, New York 10032, USA.
Shang-Jui WangInstitute for Cancer Genetics, Department of Pathology and Cell Biology, Columbia University, New York, New York 10032, USA.
Huan LiInstitute for Cancer Genetics, Department of Pathology and Cell Biology, Columbia University, New York, New York 10032, USA.
Anil K RustgiHerbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.
Wei GuInstitute for Cancer Genetics, Department of Pathology and Cell Biology, Columbia University, New York, New York 10032, USA.
Columbia University · US
Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3MTransformed Esophageal Epithelial Cells and the Tumor MicroenvironmentP01CA098101 · NCI · UNIVERSITY OF PENNSYLVANIA · PI NAKAGAWA, HIROSHI · 2003 to 2023
$31.7MRegulation of p53 acetylation and deacetylation in tumorigenesis.R01CA085533 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GU, WEI · 2000 to 2021
$5.2MNovel small molecule USP7 Inhibitors for p53 activation and cancer therapyR01CA254970 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GU, WEI · 2021 to 2025
$1.8MRegulation of SLC7A11 by p53 in cancer metabolismR01CA190477 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GU, WEI · 2016 to 2020
$1.8MMechanisms of targeting oncoprotein SET in tumor suppressionR01CA216884 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GU, WEI · 2017 to 2021
$1.8Mp53 acetylation in ferroptosis and tumor suppressionR01CA224272 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GU, WEI · 2018 to 2021
$1.5MNCI NIH HHS P01 CA098101NCI NIH HHS P30 CA013696NCI NIH HHS R01 CA085533NCI NIH HHS R01 CA190477NCI NIH HHS R01 CA216884NCI NIH HHS R01 CA224272NCI NIH HHS R01 CA254970
Abstract
Here, we showed that the acetylation-defective
Indexed as
AcetylationAnimalsCarcinogenesisCell Cycle CheckpointsEmbryo, MammalianLysineMiceMutationNeoplasmsProto-Oncogene Proteins c-mdm2SirolimusSurvival AnalysisTOR Serine-Threonine KinasesTumor Suppressor Protein p53LysineMdm2 protein, mouseProto-Oncogene Proteins c-mdm2SirolimusTOR Serine-Threonine KinasesTumor Suppressor Protein p53acetylationDDIT4/REDD1Mdm2mTORp53SESN2transcriptional regulationtumor suppression
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.